BioCentury Podcasts

•

Channel • 2 Shows

Life Sciences

Life Sciences

Every two weeks
Life Sciences

Life Sciences

Updated weekly

02/06/2021

Ep. 60 - D-Day for Aducanumab: What's at stake

Reach us by sending a text

02/06/2021

•

15 min
11/01/2022

Ep. 97 - Buysiders' Picks, plus JPM22 roundup

Reach us by sending a text

11/01/2022

•

28 min
08/10/2024

Ep. 258 - Breaking the Bear: 4Q Public Markets Preview

Biopharma buysiders and bankers at long last believe the conditions are ripe for biotech growth and outperformance, BioCentury’s Stephen Hansen says on the latest BioCentury This Week podcast. Hansen and colleagues take stock of the sector’s growth potential after three long years of the bear market as they discuss BioCentury’s 4Q24 Public Markets Preview. Also on this week’s show, Washington Editor Steve Usdin discusses his Editor’s Commentary, in which he argues that FDA leaders planned reforms for its advisory committee process fall far short of what they need to do. Usdin then delivers takeaways from the most recent edition of BioCentury This Week’s sister podcast, The BioCentury Show, which features a behind-the-scenes look at CMS’s anti-amyloid mAb decision-making process with Lee Fleisher, the former CMO of the agency. Finally, BioCentury’s Josh Berlin joins the podcast to preview the eleventh annual BioCentury-BayHelix China Healthcare Summit, which runs Oct. 30 to Nov. 1 in Shanghai. The theme of this year’s conference, which features panels of pharma BD&L leaders and blue chip investors as well as a lineup of presenting companies, is reinventing your China strategy. 00:00 - Introduction 02:13 - 4Q Public Markets Preview 16:16 - What's on at the China Summit 28:25 - Fixing FDA's Advisory Panels 34:09 - Recap: The BioCentury Show with Lee Fleisher View full story: https://www.biocentury.com/article/653793 To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

08/10/2024

•

40 min
17/04/2024

Ep. 56 - BIO’s John Crowley on the Biosecure Act

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. BIO CEO John Crowley believes that biotech is part of a “great global rivalry” between the U.S. and China. The role of biotech in determining the outcome of this rivalry, and a belief in the need for reducing U.S. reliance on Chinese biotech companies, led BIO to reverse its opposition to the Biosecure Act. Crowley acknowledges concerns that the enactment of the bill in its current form would create serious disruptions in drug development. By accepting its overall goals and engaging with Congress, BIO will have opportunities to persuade negotiate changes that will mitigate its negative consequences for biopharma companies and patients, Crowley told BioCentury Washington Editor Steve Usdin in this episode of #TheBioCenturyShow. View full story: https://www.biocentury.com/article/651990 #biotech #biopharma #pharma #biosecureact #lifescience 00:00 - Intro 03:57 - Decoupling from China 11:33 - Biosecure Act 15:48 - Rare Diseases at FDA 25:02 - Fly-outs and Big Ideas 28:05 - Changing the Narrative

17/04/2024

•

37 min
03/11/2020

Ep. 30 - ICER's Influence and Election Effects

Reach us by sending a text

03/11/2020

•

17 min
19/05/2020

Ep. 6 - New Faces for COVID-19’s Next Phase, ASCO’s Hot Topics

Reach us by sending a text

19/05/2020

•

18 min
12/04/2022

Ep. 110 - Aduhelm’s Lessons, Plus Distillery Discoveries, Rare Disease Innovation

BioCentury's editors break down CMS’s final coverage decision on amyloid mAbs for Alzheimer’s disease, focusing on what the lessons are from Aduhelm’s journey through FDA and CMS, and what sponsors of the next crop of Alzheimer's therapies should expect when seeking approval of their programs. Plus: highlights from the latest translational coverage in BioCentury’s Distillery, a call from FDA’s Patrizia Cavazzoni for increased funding to support regulatory innovation, and takeaways from Editor in Chief Simone Fishburn’s conversation on The BioCentury Show with EQRx Inc.’s Jami Rubin. Reach us by sending a text

12/04/2022

•

24 min
15/01/2021

Ep. 40 - Investors' Picks & Access to Capital in 2021

Reach us by sending a text

15/01/2021

•

16 min
16/03/2021

Ep. 49 - Vaccine Vexed; Plus Assessing Lilly's Alzheimer's Data & PDUFA Preview

Reach us by sending a text

16/03/2021

•

20 min
27/04/2021

Ep. 55 - German Plays Deliver on Data, plus Accelerated Approval on Trial

Reach us by sending a text

27/04/2021

•

19 min

BioCentury Podcasts leverage three decades of biopharma intelligence with thoughtful, accurate, and objective insights. BioCentury editors spotlight key scientific opinion leaders, corporate decision-makers, venture capitalists, and patient advocates, keeping you informed on the most current biotech stories and highlighting life science innovations.

Website

BioCentury Podcasts

Top Shows

Ep. 60 - D-Day for Aducanumab: What's at stake

Ep. 97 - Buysiders' Picks, plus JPM22 roundup

Ep. 258 - Breaking the Bear: 4Q Public Markets Preview

Ep. 56 - BIO’s John Crowley on the Biosecure Act

Ep. 30 - ICER's Influence and Election Effects

Ep. 6 - New Faces for COVID-19’s Next Phase, ASCO’s Hot Topics

Ep. 110 - Aduhelm’s Lessons, Plus Distillery Discoveries, Rare Disease Innovation

Ep. 40 - Investors' Picks & Access to Capital in 2021

Ep. 49 - Vaccine Vexed; Plus Assessing Lilly's Alzheimer's Data & PDUFA Preview

Ep. 55 - German Plays Deliver on Data, plus Accelerated Approval on Trial

About

BioCentury Podcasts

Top Shows

Top Episodes

About